Editorial: Recent advances in pediatric inflammatory diseases
Begüm Kocatürk
Füsun Özmen1 
Moshe Arditi
Seza Özen- 1Department of Basic Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
- 2Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, CA, United States
- 3Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey
Editorial on the Research Topic
Recent Advances in Pediatric Inflammatory Diseases
The immune system defends the human body from outside invaders and is critical for sustaining life in a hostile environment. It is relatively immature at birth and during infancy, evolves in childhood through exposure to multiple foreign challenges into young and mature adulthood, and gradually declines in old age (1, 2). While impaired immunity may lead to severe infections in infants and children, the immune responses may become exaggerated, leading to inflammatory and autoinflammatory diseases, or may turn against the host, leading to hyper-inflammatory disorders. Understanding the novel molecular mechanisms used by these diseases is necessary to inform the development of more effective treatment strategies.
In the Research Topic “Recent Advances in Pediatric Inflammatory Diseases”, our goal is to share the recent progress on the molecular mechanisms and a current overview on some pediatric inflammatory diseases. A potpourri of pediatric diseases such as Kawasaki disease (KD), multisystem inflammatory syndrome in children (MIS-C), juvenile idiopathic arthritis (JIA)-associated uveitis, and a review of spondyloarthritides (SpA) is presented.
The protective role of breastfeeding in KD
KD is defined as a systemic vasculitis predominantly affecting small- and medium-sized vessels. At present, KD is the leading cause of acquired heart disease in children in developed countries (3). The etiology of the disease is still unknown; it is suspected to be caused by an abnormal immune response against an infectious agent. During the acute phase of KD, innate immune hyperactivation accompanying an increase in macrophage and neutrophil counts, elevated levels of antigen–antibody complexes, IL-1β, IL-8, IL-6, and IL-17A cytokines, and a Th17-associated immune response are observed (4, 5). The treatment consists of intravenous immunoglobulin (IVIG) together with aspirin; however, the presence of IVIG-resistant patients compromises the success of this therapy (6); thus, preventive measures and alternative treatment strategies need to be explored thoroughly.
Human breast milk has an immunomodulatory role and lowers the risk of developing many immune system-mediated diseases (7). Na et al. use a large cohort to investigate whether breastfeeding also has a protective role against KD development in infants. This study reveals that it indeed reduces the incidence rate of KD for a specific amount of time, and exclusive breastfeeding extends this period even further compared to partial breastfeeding, thus suggesting a prophylactic role of human breast milk on KD vasculitis. The transfer of breast milk-derived immune components such as immunoglobulins and lymphocytes from mother to neonate helps to maintain, modulate, and instruct the infant's immunity. In addition, the organization of neonatal intestinal microbiota via nursing might very well explain the observed effects. The World Health Organization (WHO) recommends exclusive breastfeeding and partial breastfeeding for no less than 6 months and until the age of 2 years, respectively (8, 9), and the study by Na et al. once again underlines its importance.
The history of MIS-C waves
In 2020, the WHO declared the COVID-19 outbreak a global pandemic (10). In the same year, reports emerged stating the admission of children to hospitals with MIS-C. Intriguingly, the disease progression was found to resemble Kawasaki disease and toxic shock syndrome, whereafter the WHO, RCPCH, and CDC released criteria helping its differential diagnosis. The etiology remains enigmatic, but it is still believed to be an overreaction of the body's immune system possibly triggered by SARS-CoV-2. Sustained monocyte activation, IFN-γ signaling induction (11), Vβ21.3+ T-cell expansion (12), and genetic deficits in OAS-RNase L (13) are observed in patients. Kechiche et al. analyze the changing diagnostic course, symptoms, and treatment strategies for MIS-C over time. The decrease in hospitalization duration and mean diagnosis time indicates the advancement in the disease management. In addition, changes in the treatment strategy, primarily comprising the increased use of corticosteroids, seem to help to decrease the disease severity.
A summary of the current knowledge on SpA
SpA cover a group of chronic inflammatory diseases affecting the axial and peripheral joints, skin, eye, and gut (14). The etiology of SpA is also not known; thus, the diagnosis criteria and therapy regimens need to be routinely revised. Kocatürk et al. present a detailed overview of the current knowledge, encompassing the classification criteria, treatment options, and plausible risk factors associated with ankylosing spondylitis and enthesitis-related arthritis in particular. This review article also provides comprehensive evidence for HLA-B27-driven immune activation in disease pathogenesis in addition to antigen presentation, protein degradation, and microbiome-directed processes. The side effects of and inadequate response to the current treatments raise unfolded protein response and IL-23/IL-17 as new therapy targets. However, further research is warranted.
Deciphering novel autoantigens for JIA-associated uveitis
JIA is defined as an arthritis with an onset younger than 16 years of age that persists for at least 6 weeks, and it remains the most common cause of chronic arthritis in childhood (15). Diagnosis of the disease is based on clinical evaluation; however, the lack of a reliable biomarker complicates this process. A variety of autoantibodies such as anti-nuclear antibodies (ANA), rheumatoid factor, and anti-citrullinated protein antibodies show association with JIA, whereas this association is not strong for all subtypes (16). Their presence does not explicitly confirm JIA diagnosis but serves to rule out other conditions or pinpoint extra risk factors. For instance, ANA positivity is an indicator for increased risk of uveitis, and patients are advised to have regular eye exams as it may result in permanent vision loss (17).
The critical role of autoantibodies in uveitis progression is underlined by studies showing prominent B and plasma cell infiltrate in ocular inflammatory infiltrate (18) and is further supported by the success of B-cell depletion therapy in JIA-associated uveitis treatment (19). As ANA positivity is not specific to JIA-associated uveitis, Arve-Butler et al. identify novel autoantigens. They use two delicate methodologies in their discoveries, namely, a peptide array and an immunoprecipitation-based technique subsequently complemented with a bead array. Their analysis reveals 17 autoantigens showing differential reactivity between patients with and without uveitis. Another interesting aspect of autoantigens is their post-translational modification (PTM) profile. Autoantibodies directed against citrullinated or carbamylated proteins are detected in patients with JIA (16), and proteins carrying these PTMs are known to have arthritogenic properties (20, 21). Among the autoantigens identified by Arve-Butler et al., the citrullination of enolase has been previously described in JIA (22); therefore, developing an understanding of the PTM profile of the other targets deserves our attention.
Concluding remarks
Many of the established and newly emerging pediatric inflammatory diseases still preserve their mysterious origin. Each day, with the advancement of medicine, we get one step closer to better understanding these diseases. The identification of preventive measures, advancement in treatment strategies, and determination of risk factors help to unearth the molecular basis of these disorders, thus supporting and improving the identification of targeted therapies. We hope that the articles of this research topic serve as further encouragement to researchers engaged in finding the missing pieces.
Author contributions
BK, FÖ, MA, SÖ contributed to the design and writing of the manuscript and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Lewis ED, Wu D, Meydani SN. Age-associated alterations in immune function and inflammation. Prog Neuropsychopharmacol Biol Psychiatry. (2022) 118:110576. doi: 10.1016/j.pnpbp.2022.110576
2. Tsafaras GP, Ntontsi P, Xanthou G. Advantages and limitations of the neonatal immune system. Front Pediatr. (2020) 8(5). doi: 10.3389/fped.2020.00005
3. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term management of kawasaki disease: a scientific statement for health professionals from the American heart association. Circulation. (2017) 135:e927–99. doi: 10.1161/CIR.0000000000000484
4. Hara T, Yamamura K, Sakai Y. The up-to-date pathophysiology of kawasaki disease. Clin Transl Immunology. (2021) 10:e1284. doi: 10.1002/cti2.1284
5. Menikou S, Langford PR, Levin M. Kawasaki disease: the role of immune complexes revisited. Front Immunol. (2019) 10:1156. doi: 10.3389/fimmu.2019.01156
6. Bar-Meir M, Kalisky I, Schwartz A, Somekh E, Tasher D. Prediction of resistance to intravenous immunoglobulin in children with kawasaki disease. J Pediatric Infect Dis Soc. (2018) 7:25–9. doi: 10.1016/j.jpeds.2006.03.050
7. Lokossou GAG, Kouakanou L, Schumacher A, Zenclussen AC. Human breast milk: from food to active immune response with disease protection in infants and mothers. Front Immunol. (2022) 13:849012. doi: 10.3389/fimmu.2022.849012
8. Laouar A. Maternal leukocytes and infant immune programming during breastfeeding. Trends Immunol. (2020) 41:225–39. doi: 10.1016/j.it.2020.01.005
9. Mosca F, Gianni ML. Human milk: composition and health benefits. Pediatr Med Chir. (2017) 39:155. doi: 10.4081/pmc.2017.155
10. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. (2020) 91:157–60. doi: 10.23750/abm.v91i1.9397
11. Hoste L, Roels L, Naesens L, Bosteels V, Vanhee S, Dupont S, et al. TIM3+ TRBV11-2T cells and IFNgamma signature in patrolling monocytes and CD16+ NK cells delineate MIS-C. J Exp Med. (2022) 219:e20211381. doi: 10.1084/jem.20211381
12. Moreews M, Le GK, Khaldi-Plassart S, Pescarmona R, Mathieu AL, Malcus C, et al. Polyclonal expansion of TCR vbeta 21.3(+) CD4(+) and CD8(+) T cells is a hallmark of multisystem inflammatory syndrome in children. Sci Immunol. (2021) 6:eabh1516. doi: 10.1126/sciimmunol.abh1516
13. Lee D, Le PJ, Yatim A, Dong B, Aquino Y, Ogishi M, et al. Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children. Science. (2023) 379:eabo3627. doi: 10.1126/science.abo3627
14. de Winter JJ, Paramarta JE, de Jong HM, van de Sande MG, Baeten DL. Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis. RMD Open. (2019) 5:e000802. doi: 10.1136/rmdopen-2018-000802
15. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. (2007) 369:767–78. doi: 10.1016/S0140-6736(07)60363-8
16. Mahmud SA, Binstadt BA. Autoantibodies in the pathogenesis, diagnosis, and prognosis of juvenile idiopathic arthritis. Front Immunol. (2018) 9:3168. doi: 10.3389/fimmu.2018.03168
17. Foeldvari I. Ocular involvement in juvenile idiopathic arthritis: classification and treatment. Clin Rev Allergy Immunol. (2015) 49:271–7. doi: 10.1007/s12016-014-8436-9
18. Kalinina AV, van Dijk MR, de Boer JH. Infiltration of plasma cells in the Iris of children with ANA-positive anterior uveitis. Invest Ophthalmol Vis Sci. (2015) 56:6770–8. doi: 10.1167/iovs.15-17351
19. Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford. (2011) 50:1390–4. doi: 10.1093/rheumatology/ker107
20. Stoop JN, Liu BS, Shi J, Jansen DT, Hegen M, Huizinga TW, et al. Antibodies specific for carbamylated proteins precede the onset of clinical symptoms in mice with collagen induced arthritis. PLoS One. (2014) 9:e102163. doi: 10.1371/journal.pone.0102163
21. Syed RH, Gilliam BE, Moore TL. Prevalence and significance of isotypes of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis. (2008) 67:1049–51. doi: 10.1136/ard.2007.084855
Keywords: immune response, pediatrics, inflammation, autoimmunity, immune-mediated diseases
Citation: Kocatürk B, Özmen F, Arditi M and Özen S (2023) Editorial: Recent advances in pediatric inflammatory diseases. Front. Pediatr. 11:1237625. doi: 10.3389/fped.2023.1237625
Received: 9 June 2023; Accepted: 18 July 2023;
Published: 27 July 2023.
Edited and Reviewed by: Laia Alsina, Sant Joan de Déu Hospital, Spain
© 2023 Kocatürk, Özmen, Arditi and Özen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Begüm Kocatürk bkocaturk@hacettepe.edu.tr Seza Özen sezaozen@gmail.com